<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>
<BODY bgcolor="#ffffff">
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
        <TD width=100% align=center>
<B><FONT size=2 face="serif">As filed with the Securities and Exchange Commission on November 25, 2005</FONT></B></TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=right> <B><FONT size=2 face="serif">Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></TD>
</TR>
<TR>
        <TD>
<hr align="center" width="100%" size="4" noshade color="#000000" style="margin-top: -2px">
<hr align="center" width="100%" size="1" noshade color="#000000" style="margin-top: -10px">

        </TD>
</TR>
</TABLE>
<TABLE border=0 width=100% align="center" cellspacing=0 cellpadding=0>
<TR valign="bottom">
        <TD width=100% align=center>
<B><FONT size=5 face="serif">SECURITIES AND EXCHANGE COMMISSION</FONT></B></TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT face="serif">Washington, D.C. 20549</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
  <TD align=center><hr align=center width=15% size=1 noshade color="#000000">    </TD>
</TR>
</TABLE>
<TABLE border=0 width=100% align="center" cellspacing=0 cellpadding=0>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT face="serif">FORM S-8</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">REGISTRATION STATEMENT</FONT></B></TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=center>
<B><FONT size=2 face="serif">UNDER THE SECURITIES ACT OF 1933</FONT></B></TD>
</TR>
<TR>
        <TD><hr align=center width=15% size=1 noshade color="#000000">

        </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=4 face="serif">SHIRE PLC</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=center>
<B><FONT size=1 face="serif">(Exact Name of Registrant as specified in its charter)</FONT></B></TD>
</TR>
</TABLE><BR>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR align="center" valign="bottom">
        <TD width=50%>
<B><FONT size=1 face="serif">England and Wales</FONT></B></TD>
        <TD width=50%>
<B><FONT size=1 face="serif">None</FONT></B></TD>
</TR>
<TR align="center" valign="bottom">
        <TD width=50%>
<FONT size=1 face="serif">(State or other jurisdiction of</FONT></TD>
        <TD width=50%>
<FONT size=1 face="serif">(I.R.S. Employer</FONT></TD>
</TR>
<TR align="center" valign="bottom">
        <TD width=50%>
<FONT size=1 face="serif">incorporation or organization)</FONT></TD>
        <TD width=50%>
<FONT size=1 face="serif">Identification No.)</FONT></TD>
</TR>
</TABLE><BR>
<TABLE border=0 width=100% align="center" cellspacing=0 cellpadding=0>
<TR valign="bottom">
        <TD width=100% align=center>
<B><FONT size=2 face="serif">Hampshire International Business Park</FONT></B></TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">Chineham, Basingstoke</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">Hampshire RG24 8EP</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">England</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=center>
<FONT size=1 face="serif">(Address including zip code of Principal Executive Offices)</FONT></TD>
</TR>
</TABLE><BR>
<TABLE border=0 width=100% align="center" cellspacing=0 cellpadding=0>
<TR valign="bottom">
  <TD align=center>
<hr align="center" width="15%" size="1"></TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=center>
<B><FONT size=4 face="serif">SHIRE PHARMACEUTICALS GROUP PLC</FONT></B> </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=4 face="serif">LONG TERM INCENTIVE PLAN</FONT></B></TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<FONT size=1 face="serif">(Full title of the plan)</FONT>
        </TD>
</TR>
</TABLE>
<BR>
<TABLE border=0 width=100% align="center" cellspacing=0 cellpadding=0>
<TR valign="bottom">
  <TD align=center>
<hr align="center" width="15%" size="1"></TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">Scott Applebaum</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=center>
<B><FONT size=2 face="serif">Senior Vice President and U.S. Associate General Counsel</FONT></B></TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">Shire plc</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">725 Chesterbrook Blvd.</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">Wayne, Pennsylvania 19087</FONT></B>
        </TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><FONT size=2 face="serif">(484) 595-8800</FONT></B>
        </TD>
</TR>
<TR>
        <TD colspan=1 width=100%>
<hr align="center" width="15%" size="1">
        </TD>
</TR>
</TABLE>

<TABLE border=0 width=100% align="center" cellspacing=0 cellpadding=0>
<TR valign="bottom">
        <TD width=100% align=center>
<FONT size=1 face="serif">(Name, address and telephone number, including area code, of agent for service)</FONT></TD>
</TR>
<TR>
  <TD colspan=1>
    <hr align="center" width="15%" size="1">
  </TD>
</TR>
<TR valign="bottom">
  <TD align=center>&nbsp;</TD>
</TR>
<TR valign="bottom">
        <TD align=center width=100%>
<B><I><FONT size=1 face="serif">Copies to:</FONT></I></B>
        </TD>
</TR>
</TABLE>
<BR>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR align="center" valign="bottom">
        <TD width=50%>
<B><FONT size=2 face="serif">John J. McCarthy, Jr., Esq.</FONT></B></TD>
        <TD width=50%>
<B><FONT size=2 face="serif">Barbara Nims, Esq.</FONT></B></TD>
</TR>
<TR align="center" valign="bottom">
        <TD width=50%>
<B><FONT size=2 face="serif">Davis Polk &amp; Wardwell</FONT></B></TD>
        <TD width=50%>
<B><FONT size=2 face="serif">Davis Polk &amp; Wardwell</FONT></B></TD>
</TR>
<TR align="center" valign="bottom">
        <TD width=50%>
<B><FONT size=2 face="serif">450 Lexington Avenue</FONT></B></TD>
        <TD width=50%>
<B><FONT size=2 face="serif">450 Lexington Avenue</FONT></B></TD>
</TR>
<TR align="center" valign="bottom">
        <TD width=50%>
<B><FONT size=2 face="serif">New York, New York 10017</FONT></B></TD>
        <TD width=50%>
<B><FONT size=2 face="serif">New York, New York 10017</FONT></B></TD>
</TR>
<TR align="center" valign="bottom">
        <TD width=50%>
<B><FONT size=2 face="serif">212-450-4000</FONT></B></TD>
        <TD width=50%>
<B><FONT size=2 face="serif">212-450-4000</FONT></B></TD>
</TR>
<TR align="center" valign="bottom">
  <TD colspan="2">
<hr align="center" width="15%" size="1"></TD>
  </TR>
</TABLE>
<div align="center"><b><font size=2 face="serif">CALCULATION OF REGISTRATION FEE</font></b>
</div>
<TABLE border=1 width=100% cellspacing=0 cellpadding=4>
<TR valign="bottom">
  <TD align=center>
    <B><FONT size=1 face="serif">&nbsp;&nbsp;Title of Securities to be Registered</FONT></B></TD>
        <TD width=16% align=center>
      <B><FONT size=1 face="serif">Amount to be<br>
</FONT></B>
      <B><FONT size=1 face="serif">Registered</FONT></B></TD>
        <TD width=16% align=center>
<B><FONT size=1 face="serif">Proposed Maximum<br>
</FONT></B>
<B><FONT size=1 face="serif">Offering Price<br>
</FONT></B>
<B><FONT size=1 face="serif">Per Share</FONT></B></TD>
        <TD width=16% align=center>
<B><FONT size=1 face="serif">Proposed Maximum<br>
</FONT></B>
<B><FONT size=1 face="serif">Aggregate<br>
</FONT></B>
<B><FONT size=1 face="serif">Offering Price</FONT></B></TD>
        <TD width=16% align=center>
      <B><FONT size=1 face="serif">Amount of<br>
</FONT></B>
      <B><FONT size=1 face="serif">Registration Fee</FONT></B></TD>
</TR>
<TR valign="bottom">
  <TD align=center>
<FONT size=2 face="serif">Ordinary Shares, nominal value<br>
</FONT>
<FONT size=2 face="serif">&#163;3.50 per Ordinary Share(1)(4)</FONT></TD>
        <TD width=16% align=center valign="middle">
      <FONT size=2 face="serif">986,935(2)</FONT></TD>
        <TD width=16% align=center valign="middle">      <font size="2" face="serif">$12.25(3)</font></TD>
        <TD width=16% align=center valign="middle">      <font size="2" face="serif">$12,091,452.66(3)</font></TD>
        <TD width=16% align=center valign="middle">      <font size="2" face="serif">$1423.16</font></TD>
</TR>
</TABLE>

<P>
  <FONT size=2 face="serif">In addition, pursuant to Rule 416 under the Securities
  Act of 1933, as amended (the &#147;Securities Act&#148;), there is also being registered an indeterminate number of common shares which may become issuable as a result
of the anti-dilution provisions of the Shire Pharmaceuticals Group plc Long Term Incentive Plan (the &#147;Plan&#148;). </FONT></P>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="5%" align="left" valign="top"><font size=2 face="serif">(1)</font></td>
    <td width="95%" align="left" valign="top"><font size=2 face="serif">American
        Depositary Receipts evidencing American Depositary Shares deliverable
        on deposit of the Ordinary Shares, nominal value &#163;3.50 pence per
        share (the "Ordinary Shares"), of Shire plc (&#147;Shire&#148; or the &#147;Registrant&#148;)
        have been registered pursuant to a separate Registration Statement on
        Form F-6
        (Registration No. 333-129848)
        filed with the Securities and Exchange Commission (the &#147;Commission&#148;).
    Each American Depositary Share represents three Ordinary Shares.</font></td>
  </tr>
  <tr>
    <td align="left" valign="top">&nbsp;</td>
    <td align="left" valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td align="left" valign="top"><font size=2 face="serif">(2)</font><td align="left" valign="top"><font size=2 face="serif">The number of Ordinary
        Shares being registered represents the estimated maximum aggregate number
    deliverable to employees in the United States pursuant to the Plan.</font></td>
  </tr>
  <tr>
    <td align="left" valign="top">&nbsp;</td>
    <td align="left" valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td align="left" valign="top"><font size=2 face="serif">(3)</font></td>
        <td align="left" valign="top"><font size=2 face="serif">In accordance with
        Rule 457(h), the proposed maximum offering price per share has been
        calculated pursuant to Rule 457(c). The translation of the average of
        the high and low Ordinary Share prices on November 21, 2005
        on the London Stock Exchange from 7.1375 pounds Sterling into U.S.
        Dollars has been made at the noon buying rate on November 21,
        2005 of &#163;1=U.S.&#36; 1.7165. The resulting proposed maximum
        offering price per share, U.S.&#36; 12.25, has been multiplied
        by the amount of shares to be registered to obtain the proposed maximum
    aggregate offering price of U.S.&#36; 12,091,452.66.</font></td>
  </tr>
  <tr>
    <td align="left" valign="top">&nbsp;</td>
    <td align="left" valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td align="left" valign="top"><font size=2 face="serif">(4)</font></td>
    <td align="left" valign="top"><font size=2 face="serif">On November 25,
        2005, Shire Pharmaceuticals Group plc (the &#147;Predecessor Registrant&#148;)
        completed a reorganization (the &#147;Reorganization&#148;) of its corporate
        structure through a scheme of arrangement pursuant to Section 425 of
        the United Kingdom Companies Act 1985, resulting in the interposition
        of a new holding company, Shire plc. Pursuant to the scheme of arrangement,
        ordinary shares, each having a nominal value of &#163;3.50, of the Registrant
        were substituted for ordinary shares, each having a nominal value of &#163;0.05,
        of the Predecessor Registrant. Subsequent to the Reorganization and
        in connection therewith, the Registrant will undertake a capital reduction
        resulting in a decrease in the per share nominal value of its ordinary
        shares from &#163;3.50 to &#163;0.05, which is expected to be effective
    on November 29, 2005.</font></td>
  </tr>
</table>
<P>
  <FONT size=1 face="serif"> </FONT></P>
<hr align="center" width="100%" size="1" noshade color="#000000" style="margin-top: -2px">
<hr align="center" width="100%" size="4" noshade color="#000000" style="margin-top: -10px">
<PAGE>
<br>
<br>
<P align="center">
<B><FONT size=2 face="serif">PART I </FONT></B></P>
<P align="center">
<B><FONT size=2 face="serif">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS </FONT></B></P>
<P>
<B><FONT size=2 face="serif">ITEM 1. PLAN INFORMATION* </FONT></B></P>
<P>
<B><FONT size=2 face="serif">ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION* </FONT></B></P>
<TABLE WIDTH=100% border=0 cellspacing=0 cellpadding=0>
<TR>
        <TD width="6%" align="center" valign=top nowrap>
<FONT size=2 face="serif">*</FONT></TD>
        <TD width=94% align="left" valign="top">
<FONT size=2 face="serif">Information required by Part I of Form S-8 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the Note to Part I of Form S-8.
The documents containing the information specified in Part I will be delivered to the participants in the plan covered by this Registration Statement as required by Rule 428(b). Such documents are not being filed with the Commission as part of this
Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424(b) under the Securities Act.</FONT></td>
</TR>
</TABLE>
<P align="center">
<B><FONT size=2 face="serif">PART II </FONT></B></P>
<P align="center">
<B><FONT size=2 face="serif">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT </FONT></B></P>
<P>
<B><FONT size=2 face="serif">ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE </FONT></B></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following documents are incorporated herein by reference in this Registration Statement: </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Predecessor Registrant&#146;s Annual Report on Form 10-K for the year ended December 31, 2004. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(2) All reports filed by us or by the Predecessor Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since December 31, 2004. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(3) The description of the Registrant&#146;s Ordinary Shares contained in the Registrant&#146;s Current Report on Form 8-K filed on November 25, 2005, including any amendment or report filed
for the purpose of updating such description. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">All other documents filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date hereof and prior to the filing of a
post-effective amendment which indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part
hereof from the date of filing of such documents. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Any statement contained herein or made in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration
Statement to the extent that a statement contained herein, or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. </FONT></P>
<P>
<B><FONT size=2 face="serif">ITEM 4. DESCRIPTION OF SECURITIES </FONT></B></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>
<P>
<B><FONT size=2 face="serif">ITEM 5. INTEREST OF NAMED EXPERTS AND COUNSEL </FONT></B></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None </FONT></P>
<br>
<br>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>
<P>
<B><FONT size=2 face="serif">ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS </FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Except as hereinafter set forth, there is no charter provision, by-law, contract, arrangement or statute under which any director or officer of the Registrant is insured or indemnified in any
manner against any liability which he may incur in his capacity as such. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Pursuant to Paragraph 144 of the Articles of Association of the Registrant, every person who was or is a director of the Company may, but is not required to, be indemnified out of the assets of
the Registrant for any liability for which the Company may lawfully indemnify that director. </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s Memorandum and Articles of Association provide in relevant part: </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Article 144. Indemnity of Directors </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the
    provisions of the Companies Acts, the Company may indemnify any director of
    the </FONT><FONT size=2 face="serif">Company or of any associated company against
    any liability and may purchase and maintain for any director of the Company
    or any associated company insurance against any liability.</FONT></p>
</blockquote>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The relevant provisions of the Companies Act 1985, as amended, are Sections 309A, 309B and 309C, which provide: </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;&sect; 309A: Provisions protecting directors from liability. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(1) This section applies in relation to any liability attaching to a director of a company in connection with any negligence, default, breach of duty or breach of trust by him in relation to
the company. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(2) Any provision which purports to exempt (to any extent) a director of a company from any liability within subsection (1) is void. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(3) Any provision by which a company directly or indirectly provides (to any extent) an indemnity for a director of &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) the company, or </FONT></p>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(b) an associated company, </FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">against any liability within subsection (1) is void </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is subject to subsections (4) and (5). </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) Subsection (3) does not apply to a qualifying third party indemnity provision (see section 309B(1)). </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) Subsection (3) does not prevent a company from purchasing and maintaining for a director of &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) the company, or </FONT></p>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(b) an associated company, </FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;insurance against any liability within subsection (1). </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) In this section &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&#147;associated company&#148;, in relation to a company (&#147;C&#148;), means a company which is C&#146;s subsidiary, or C&#146;s holding company or a subsidiary of C&#146;s holding company; </FONT></p>
  <p>
    <FONT size=2 face="serif">&#147;provision&#148; means a provision of any nature, whether or not it is contained in a company&#146;s articles or in any contract with a company.&#148; </FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;&sect; 309B: Qualifying third party indemnity provisions. </FONT></P>
<P align="center">
<FONT size=2 face="serif">2 </FONT></P>
<br>
<br>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(1) For the purposes of section 309A(4) a provision is a qualifying third party indemnity provision if it is a provision such as is mentioned in section 309A(3) in relation to which conditions
A to C below are satisfied. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(2) Condition A is that the provision does not provide any indemnity against any liability incurred by the director &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) to the company, or </FONT></p>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(b) to any associated company. </FONT></p>
</blockquote>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(3) Condition B is that the provision does not provide any indemnity against any liability incurred by the director to pay &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) a fine imposed in criminal proceedings, or </FONT></p>
  <p> &nbsp;&nbsp;<FONT size=2 face="serif">(b) a sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (however arising). </FONT></p>
</blockquote>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(4) Condition C is that the provision does not provide any indemnity against any liability incurred by the director &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) in defending any criminal proceedings in which he is convicted, or </FONT></p>
  <p> &nbsp;&nbsp;<FONT size=2 face="serif">(b) in defending any civil proceedings brought by the company, or an associated company, in which judgment is given against him, or </FONT></p>
  <p> &nbsp;&nbsp;<FONT size=2 face="serif">(c) in connection with any application under any of the following provisions in which the court refuses to grant him relief, namely &#150;</FONT></p>
  <blockquote>
    <p align="left">
      <FONT size=2 face="serif">(i) section 144(3) or (4) (acquisition of shares by innocent nominee), or </FONT></p>
    <p align="left">
      <FONT size=2 face="serif">(ii) section 727 (general power to grant relief in case of honest and reasonable conduct). </FONT></p>
  </blockquote>
</blockquote>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(5) In paragraph (a), (b) or (c) of subsection (4) the reference to any such conviction, judgment or refusal of relief is a reference to one that has become final. </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) For the purposes of subsection (5) a conviction, judgment or refusal of relief becomes final &#150;</FONT></P>
<blockquote>
  <p align="left">
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) if not appealed against, at the end of the period for bringing an appeal, or </FONT></p>
  <p align="left">
    <FONT size=2 face="serif">&nbsp;&nbsp;(b) if appealed against, at the time when the appeal (or any further appeal) is disposed of. </FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) An appeal is disposed of &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) if it is determined and the period for bringing any further appeal has ended, or </FONT></p>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(b) if it is abandoned or otherwise ceases to have effect. </FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) In this section &#147;associated company&#148; and &#147;provision&#148; have the same meaning as in section 309A.&#148; </FONT></P>
<P>
<FONT size=2 face="serif"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;&sect; 309C: Disclosure of qualifying third party indemnity provisions. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(1) Subsections (2) and (3) impose disclosure requirements in relation to a directors&#146; report under section 234 in respect of a financial year. </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) If &#150; </FONT></P>
<P align="center">
<FONT size=2 face="serif">3 </FONT></P>
<br>
<br>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>
<blockquote>
  <p> &nbsp;&nbsp;<FONT size=2 face="serif">(a) at the time when the report is approved under section 234A, any qualifying third party indemnity provision (whether made by the company or otherwise) is in force for the benefit of one or
    more directors of the company, or </FONT></p>
  <p> &nbsp;&nbsp;<FONT size=2 face="serif">(b) at any time during the financial year, any such provision was in force for the benefit of one or more persons who were then directors of the company,</FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">the report must state that any such provision is or (as the case may be) was so in force. </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) If the company has made a qualifying third party indemnity provision and &#150; </FONT></P>
<blockquote>
  <p> &nbsp;&nbsp;<FONT size=2 face="serif">(a) at the time when the report is approved under section 234A, any qualifying third party indemnity provision made by the company is in force for the benefit of one or more directors of an
    associated company, or </FONT></p>
  <p> &nbsp;&nbsp;<FONT size=2 face="serif">(b) at any time during the financial year, any such provision was in force for the benefit of one or more persons who were then directors of an associated company, </FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">the report must state that any such provision is or (as the case may be) was so in force. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(4) Subsection (5) applies where a company has made a qualifying third party indemnity provision for the benefit of a director of the company or of an associated company. </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) Section 318 shall apply to &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(a) the company, and </FONT></p>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;(b) if the director is a director of an associated company, the associated company, </FONT></p>
</blockquote>
<P>
<FONT size=2 face="serif">as if a copy of the provision, or (if it is not in writing) a memorandum setting out its terms, were included in the list of documents in section 318(1). </FONT></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) In this section &#150; </FONT></P>
<blockquote>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;&#147;associated company&#148; and &#147;provision&#148; have the same meaning as in section 309A; and </FONT></p>
  <p>
    <FONT size=2 face="serif">&nbsp;&nbsp;&#147;qualifying third party indemnity provision&#148; has the meaning given by section 309B(1).&#148; </FONT></p>
</blockquote>
<P><FONT size=2 face="serif">Shire plc has entered into separate deeds of indemnity with each of its directors, and anticipates entering into deeds of indemnity with directors appointed in future, pursuant to the power under Article 144 of its Articles of Association. </FONT></P>
<P><FONT size=2 face="serif">The provisions of the deeds of indemnity are substantially identical and are intended to indemnify the directors of Shire plc to the full extent permitted by Sections 309A, 309B and 309C of the Companies Act 1985 (as amended) (the &#147;Act&#148;), as described above. </FONT></P>
<P><FONT size=2 face="serif">The deeds have two key provisions. Under the first (clause 2.1 of each deed), Shire plc indemnifies the director against any &#147;liability&#148; incurred by the director's acts or omissions, or by virtue of his holding office as a director of Shire plc, which arises out of a claim brought against the director by a &#147;third party&#148;. &#147;Liability&#148; includes damages awarded against the director by a court (in certain circumstances) and also the cost of defending any claim. A &#147;third party&#148; is any party other than Shire plc, or a company associated with Shire plc. This indemnity is subject to certain limitations to its scope (described in section 309B of the Act) to ensure its qualification as a &#147;third party qualifying indemnity provision&#148; permitted by the Act. </FONT></P>
<P><FONT size=2 face="serif">If the director is convicted of a criminal offence or is refused relief by a court in relation to certain applications under the Act, that director must reimburse Shire plc for any amount in respect of the costs of defending the relevant proceedings advanced by Shire plc pursuant to clause 2.1. </FONT></P>
<P><FONT size=2 face="serif">Under the second key provision (clause 2.4 of each deed) Shire plc indemnifies the director solely against any liability the director incurs in defending a criminal claim or civil action brought against the director by, or on behalf of, Shire plc or a company associated with Shire plc (the director is not permitted to be indemnified in respect of any liability to Shire plc or an associated company, of itself). </FONT></P>
<P><FONT size=2 face="serif">However, the indemnity will cease, and the director will have to reimburse Shire plc for funds paid out under clause 2.4, if the director is convicted in criminal proceedings, if judgment is given against him in civil proceedings, or if he is refused relief by the court in relation to certain applications under the Act.</FONT></P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Shire plc maintains an insurance policy for its directors and officers in respect of liabilities arising out of any act, error or omission while acting in their capacities as directors or
  officers of Shire plc or its affiliated companies. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT size=2 face="serif">ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED </FONT></B></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable. </FONT></P>
<P>
<B><FONT size=2 face="serif">ITEM 8. EXHIBITS </FONT></B></P>
<TABLE WIDTH=100% border=0 cellspacing=0 cellpadding=0>
<TR>
  <TD width="3%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="3%" align="left" valign=top nowrap>
<FONT size=2 face="serif">4.1</FONT></TD>
        <TD width=94% align="left">
<FONT size=2 face="serif">Memorandum and Articles of Association of Shire plc*</FONT>   </TD>
</TR>
<TR>
  <TD>&nbsp;</TD>

  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR><TR>
        <TD width="3%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="3%" align="left" valign=top nowrap>
<FONT size=2 face="serif">5.1</FONT></TD>
        <TD width=94% align="left">
<FONT size=2 face="serif">Opinion of Slaughter and May</FONT>   </TD>
</TR>
<TR>
  <TD>&nbsp;</TD>

  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR><TR>
        <TD width="3%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="3%" align="left" valign=top nowrap>
<FONT size=2 face="serif">23.1</FONT></TD>
        <TD width=94% align="left">
<FONT size=2 face="serif">Consent of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm</FONT>    </TD>
</TR>
<TR>
  <TD>&nbsp;</TD>

  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR><TR>
        <TD width="3%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="3%" align="left" valign=top nowrap>
<FONT size=2 face="serif">23.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
        <TD width=94% align="left">
<FONT size=2 face="serif">Consent of Slaughter and May (included in Exhibit 5.1)</FONT> </TD>
</TR>
</TABLE>
<P align="center">
<FONT size=2 face="serif">4 </FONT></P>
<br>
<br>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>
<TABLE WIDTH=100% border=0 cellspacing=0 cellpadding=0>
<TR>
  <TD width="3%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="3%" align="left" valign=top nowrap>
<FONT size=2 face="serif">24.1</FONT></TD>
        <TD width=94% align="left" valign="top">
<FONT size=2 face="serif">Powers of attorney (included on the signature pages hereof)</FONT>    </TD>
</TR>
<TR>
  <TD>&nbsp;</TD>

  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
</TR><TR>
        <TD width="3%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="3%" align="left" valign=top nowrap>
<FONT size=2 face="serif">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
        <TD width=94% align="left" valign="top">
<FONT size=2 face="serif">Shire Pharmaceuticals Group plc Long Term Incentive Plan (as amended and restated on October 22, 2005)</FONT> </TD>
</TR>
</TABLE>
<TABLE WIDTH=100% border=0 cellspacing=0 cellpadding=0>
<TR>
  <TD colspan="2" align="left" valign=top nowrap>
    <hr align="left" width="10%" size="1"></TD>
  </TR>
<TR>
  <TD width="3%" align="left" valign=top nowrap><font size=2 face="serif">*</font></TD>
        <TD width="97%" align="left" valign=top> <FONT size=2 face="serif">Incorporated
by reference to Exhibit 3.01 to Shire&#146;s Current Report on Form 8-K filed
with the Securities and Exchange Commission on November 25, 2005.</FONT></TD>
  </TR>
</TABLE>
<P>
<B><FONT size=2 face="serif">ITEM 9. REQUIRED UNDERTAKINGS </FONT></B></P>
<P>
<FONT size=2 face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Company hereby undertakes: </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement to include any material information with respect to the plan of
distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><I><FONT size=2 face="serif">bona fide</FONT></I><FONT size=2 face="serif"> offering thereof. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(b) The undersigned Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company&#146;s annual report pursuant to Section 13(a)
or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><I><FONT size=2 face="serif">bona fide</FONT></I><FONT size=2 face="serif">
offering thereof. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing
provisions, or otherwise, the Company has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P>
<P align="center">
<FONT size=2 face="serif">5 </FONT></P>

<br>
<br>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>
<P align="center">
<B><FONT size=2 face="serif">EXPERTS </FONT></B></P>
<P>
  <font size="2">&nbsp;&nbsp;&nbsp;&nbsp; The financial statements,&nbsp;the related financial
statement schedules, and management's report on the effectiveness of internal
control over financial reporting incorporated in this&nbsp; registration statement
by reference from the&nbsp;Annual Report&nbsp; on Form 10-K of Shire Pharmaceuticals
Group plc for the year ended December 31, 2004 have been audited by Deloitte &amp; Touche
LLP, an independent registered public accounting firm, as stated in their report,
which is incorporated herein by reference, and have been so incorporated in reliance
upon the report of such firm given upon their authority as experts in accounting
and auditing. </font></P>
<p><br>
</p>
<p align="center"><font size="2" face="serif">6</font><br>
</p>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>

<P align="center">
<B><FONT size=2 face="serif">SIGNATURES </FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">The Registrant, pursuant to the requirements of the Securities Act certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Basingstoke, England, on this 25</FONT><SUP><FONT size=2 face="serif">th</FONT></SUP><FONT size=2 face="serif"> day of
November, 2005. </FONT></P>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
  <TD width=45% align=left>&nbsp;</TD>
        <TD colspan=2 align=left nowrap>
<FONT size=2 face="serif">SHIRE PLC</FONT></TD>
  </TR>
<TR>
  <TD width="45%" align="left">&nbsp;</TD>
        <TD width="5%" align="left" nowrap>&nbsp;

        </TD>
    <TD width="50%" align="left">&nbsp;</TD>
</TR>
<TR>
  <TD width="45%" align="left">&nbsp;</TD>
        <TD width="5%" align="left" nowrap>&nbsp;

        </TD>
    <TD width="50%" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
  <TD width=45% align=left>&nbsp;</TD>
        <TD width=5% align=left nowrap>
<FONT size=2 face="serif">By:</FONT></TD>
        <TD width=50% align=left>
<FONT size=2 face="serif">/s/ Matthew Emmens</FONT></TD>
</TR>
<TR>
  <TD width="45%" align="left"></TD>
        <TD width="5%" align="left" nowrap>
        </TD>
        <TD width="50%" align="left">
<HR align="left" width="80%" size=1 noshade>
        </TD>
</TR>
<TR valign="bottom">
  <TD width=45% align=left>&nbsp;</TD>
        <TD width=5% align=left nowrap>
<FONT size=2 face="serif">Name:&nbsp;</FONT></TD>
        <TD width=50% align=left>
<FONT size=2 face="serif">Matthew Emmens</FONT></TD>
</TR>
<TR valign="bottom">
  <TD width=45% align=left>&nbsp;</TD>
        <TD width=5% align=left nowrap>
<FONT size=2 face="serif">Title:</FONT></TD>
        <TD width=50% align=left>
<FONT size=2 face="serif">Chief Executive Officer</FONT></TD>
</TR>
</TABLE>
<BR>
<P align="center">
<B><FONT size=2 face="serif">POWER OF ATTORNEY </FONT></B></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Know all men by these presents, that each person whose signature appears below, constitutes and appoints Matthew Emmens and Angus Russell and each of them, our true and lawful attorneys-in-fact
and agents, with full power of substitution and resubstitution, to do any all acts and things and execute, in the name of the undersigned, any and all instruments which said attorneys-in-fact and agents may deem necessary or advisable in order to
enable Shire plc to comply with the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and any requirements of the Securities and Exchange Commission (the &#147;Commission&#148;) in respect thereof, in connection with the filing
with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such
Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, to sign any and all applications, registration statements, notices or
other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might
or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P>
<P>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT size=2 face="serif">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.</FONT></P>
<P align="center">
<font size="2" face="serif">7</font></P>
<br>
<br>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
  <TD width=30% align=center> <B><U><FONT size=1 face="serif">Signature</FONT></U></B></TD>
  <TD width=5% align=center>&nbsp;</TD>
  <TD width=40% align=center> <B><U><FONT size=1 face="serif">Title</FONT></U></B></TD>
  <TD width=5% align=left>&nbsp;</TD>
  <TD width=20% align=center> <B><U><FONT size=1 face="serif">Date</FONT></U></B></TD>
  </TR>
<TR>
        <TD width="30%" align="left">&nbsp;

        </TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="40%" align="left">&nbsp;</TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="20%" align="center">&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;Dr. James Cavanaugh</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>
<FONT size=2 face="serif">Chairman and Non-Executive Director</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width="40%" align="left">&nbsp;
        </TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">Dr. James Cavanaugh</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>&nbsp;

        </TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;Matthew Emmens</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left><font size=2 face="serif">Chief Executive Officer</font></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width=40% align=left valign="bottom"> <FONT size=2 face="serif">(Principal
            executive officer)</FONT></TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">Matthew Emmens</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>&nbsp;

        </TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;Angus Russell</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left><font size=2 face="serif">Chief Financial Officer
            (Principal financial</font> </TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width=40% align=left valign="bottom"> <FONT size=2 face="serif">officer
            and principal accounting officer)</FONT></TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">Angus Russell</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
<TR>
        <TD width="30%" align="left">&nbsp;

        </TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="40%" align="left">&nbsp;</TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="20%" align="center">&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;Dr. Barry Price</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>
<FONT size=2 face="serif">Senior Non-Executive Director</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width="40%" align="left">&nbsp;
        </TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">Dr. Barry Price</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
<TR>
        <TD width="30%" align="left">&nbsp;

        </TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="40%" align="left">&nbsp;</TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="20%" align="center">&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;The Hon. James A. Grant</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>
<FONT size=2 face="serif">Non-Executive Director</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width="40%" align="left">&nbsp;
        </TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">The Hon. James A. Grant</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
<TR>
        <TD width="30%" align="left">&nbsp;

        </TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="40%" align="left">&nbsp;</TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="20%" align="center">&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;Ronald Nordmann</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>
<FONT size=2 face="serif">Non-Executive Director</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width="40%" align="left">&nbsp;
        </TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">Ronald Nordmann</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
<TR>
        <TD width="30%" align="left">&nbsp;

        </TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="40%" align="left">&nbsp;</TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="20%" align="center">&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;Robin Buchanan</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>
<FONT size=2 face="serif">Non-Executive Director</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width="40%" align="left">&nbsp;
        </TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">Robin Buchanan</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
<TR>
        <TD width="30%" align="left">&nbsp;

        </TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="40%" align="left">&nbsp;</TD>
    <TD width="5%" align="left">&nbsp;</TD>
    <TD width="20%" align="center">&nbsp;</TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">/s/&nbsp;David Kappler</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>
<FONT size=2 face="serif">Non-Executive Director</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>
<FONT size=2 face="serif">November 25, 2005</FONT></TD>
</TR>
<TR>
        <TD width="30%" align="left">
<HR noshade size=1>
        </TD>
        <TD width="5%" align="left">&nbsp;</TD>
        <TD width="40%" align="left">&nbsp;
        </TD>
        <TD width="5%" align="left"></TD>
        <TD width="20%" align="center">
        </TD>
  </TR>
<TR valign="bottom">
        <TD width=30% align=left>
<FONT size=2 face="serif">David Kappler</FONT></TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=40% align=left>&nbsp;</TD>
        <TD width=5% align=left>&nbsp;</TD>
        <TD width=20% align=center>&nbsp;

        </TD>
  </TR>
</TABLE>
<BR>
<TABLE border=0 width=100% cellspacing=0 cellpadding=0>
<TR valign="bottom">
        <TD width=100% align=left>
<B><FONT size=2 face="serif">AUTHORIZED US REPRESENTATIVE</FONT></B></TD>
</TR>
<TR>
        <TD>&nbsp;

        </TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=left>
<FONT size=2 face="serif">/s/ Scott Applebaum</FONT></TD>
</TR>
<TR>
        <TD>
<HR align="left" width="30%" size=1 noshade>
        </TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=left>
<FONT size=2 face="serif">Shire plc</FONT></TD>
</TR>
<TR>
        <TD>&nbsp;

        </TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=left>
<FONT size=2 face="serif">By: Scott Applebaum, as the duly authorized</FONT></TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=left>
<FONT size=2 face="serif">representative of Shire plc in the United</FONT></TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=left>
<FONT size=2 face="serif">States</FONT></TD>
</TR>
<TR>
        <TD>&nbsp;

        </TD>
</TR>
<TR valign="bottom">
        <TD width=100% align=left>
<FONT size=2 face="serif">Date: &nbsp;&nbsp;&nbsp;November 25, 2005</FONT></TD>
</TR>
</TABLE><BR>
<P align="center">
<font size="2" face="serif">8</font></P>
<br>
<br>
<hr size=3 color=GRAY noshade>
<PAGE>
<br>
<br>
<P align="center">
<B><FONT size=2 face="serif">EXHIBIT INDEX </FONT></B></P>
<TABLE WIDTH=100% border=0 cellspacing=0 cellpadding=0>
<TR>
  <TD width="5%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="5%" align="left" valign=top nowrap>
<FONT size=2 face="serif">4.1</FONT></TD>
        <TD width=90% align="left" valign="top">
<FONT size=2 face="serif">Memorandum and Articles of Association of Shire plc*</FONT>   </TD>
</TR>
<TR>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="90%" align="left" valign="top">&nbsp;</TD>
</TR><TR>
        <TD width="5%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="5%" align="left" valign=top nowrap>
<FONT size=2 face="serif">5.1</FONT></TD>
        <TD width=90% align="left" valign="top">
<FONT size=2 face="serif">Opinion of Slaughter and May</FONT>   </TD>
</TR>
<TR>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="90%" align="left" valign="top">&nbsp;</TD>
</TR><TR>
        <TD width="5%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="5%" align="left" valign=top nowrap>
<FONT size=2 face="serif">23.1</FONT></TD>
        <TD width=90% align="left" valign="top">
<FONT size=2 face="serif">Consent of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm</FONT>    </TD>
</TR>
<TR>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="90%" align="left" valign="top">&nbsp;</TD>
</TR><TR>
        <TD width="5%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="5%" align="left" valign=top nowrap>
<FONT size=2 face="serif">23.2</FONT></TD>
        <TD width=90% align="left" valign="top">
<FONT size=2 face="serif">Consent of Slaughter and May (included in Exhibit 5.1)</FONT> </TD>
</TR>
<TR>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="90%" align="left" valign="top">&nbsp;</TD>
</TR><TR>
        <TD width="5%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="5%" align="left" valign=top nowrap>
<FONT size=2 face="serif">24.1</FONT></TD>
        <TD width=90% align="left" valign="top">
<FONT size=2 face="serif">Powers of attorney (included on the signature pages hereof)</FONT>    </TD>
</TR>
<TR>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="5%" align="left" valign="top">&nbsp;</TD>
  <TD width="90%" align="left" valign="top">&nbsp;</TD>
</TR><TR>
        <TD width="5%" align="left" valign=top nowrap>&nbsp;</TD>
        <TD width="5%" align="left" valign=top nowrap>
<FONT size=2 face="serif">99.1</FONT></TD>
        <TD width=90% align="left" valign="top">
<FONT size=2 face="serif">Shire Pharmaceuticals Group plc Long Term Incentive Plan (as amended and restated on October 22, 2005)</FONT> </TD>
</TR>
</TABLE>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td colspan="2" align="left" valign="top">
<hr align="left" width="10%" size="1"></td>
  </tr>
  <tr>
    <td width="5%" align="left" valign="top"><font size=2 face="serif">*</font></td>
    <td width="97%" align="left" valign="top"><font size=2 face="serif">Incorporated by
        reference to Exhibit 3.01 to Shire&#146;s Current Report on Form 8-K
    filed with the Securities and Exchange Commission on November 25, 2005. </font></td>
  </tr>
</table>
<P>
<FONT size=2 face="serif"> </FONT></P>

<div align="center"><br>
    <font size="2" face="serif">9</font><br>
</div>
<hr size=3 color=GRAY noshade>
<br>
<br>
</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "nov2505_s8-ltip.htm", "secsgml_size_bytes": 58811}]
{"company-data": {"conformed-name": "Shire plc", "cik": "0000936402", "assigned-sic": "2834", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-129960", "film-number": "051226661"}, "business-address": {"street1": "HAMPSHIRE INTL BUSINESS PARK", "street2": "CHINEHAM BASINGSTOKE", "city": "HAMPSHIRE ENGLAND RG", "state": "X0", "zip": "-", "phone": "1264333455"}, "mail-address": {"street1": "HAMPSHIRE INTL BUSINESS PARK", "street2": "CHINEHAM BASINGSTOKE", "city": "HAMPSHIRE ENGLAND RG", "state": "X0", "zip": "-"}, "former-company": {"former-conformed-name": "SHIRE PHARMACEUTICALS GROUP PLC", "date-changed": "19980302"}}
As filed with the Securities and Exchange Commission on November 25, 2005
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
SHIRE PLC
(Exact Name of Registrant as specified in its charter)
England and Wales
None
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
Hampshire International Business Park
Chineham, Basingstoke
Hampshire RG24 8EP
England
(Address including zip code of Principal Executive Offices)
SHIRE PHARMACEUTICALS GROUP PLC
LONG TERM INCENTIVE PLAN
(Full title of the plan)
Scott Applebaum
Senior Vice President and U.S. Associate General Counsel
Shire plc
725 Chesterbrook Blvd.
Wayne, Pennsylvania 19087
(484) 595-8800
(Name, address and telephone number, including area code, of agent for service)
Copies to:
John J. McCarthy, Jr., Esq.
Barbara Nims, Esq.
Davis Polk & Wardwell
Davis Polk & Wardwell
450 Lexington Avenue
450 Lexington Avenue
New York, New York 10017
New York, New York 10017
212-450-4000
212-450-4000
CALCULATION OF REGISTRATION FEE
Title of Securities to be Registered
Amount to be
Registered
Proposed Maximum
Offering Price
Per Share
Proposed Maximum
Aggregate
Offering Price
Amount of
Registration Fee
Ordinary Shares, nominal value
£3.50 per Ordinary Share(1)(4)
986,935(2)
$12.25(3)
$12,091,452.66(3)
$1423.16
In addition, pursuant to Rule 416 under the Securities
  Act of 1933, as amended (the "Securities Act"), there is also being registered an indeterminate number of common shares which may become issuable as a result
of the anti-dilution provisions of the Shire Pharmaceuticals Group plc Long Term Incentive Plan (the "Plan").
(1)
American
        Depositary Receipts evidencing American Depositary Shares deliverable
        on deposit of the Ordinary Shares, nominal value £3.50 pence per
        share (the "Ordinary Shares"), of Shire plc ("Shire" or the "Registrant")
        have been registered pursuant to a separate Registration Statement on
        Form F-6
        (Registration No. 333-129848)
        filed with the Securities and Exchange Commission (the "Commission").
    Each American Depositary Share represents three Ordinary Shares.
(2)
The number of Ordinary
        Shares being registered represents the estimated maximum aggregate number
    deliverable to employees in the United States pursuant to the Plan.
(3)
In accordance with
        Rule 457(h), the proposed maximum offering price per share has been
        calculated pursuant to Rule 457(c). The translation of the average of
        the high and low Ordinary Share prices on November 21, 2005
        on the London Stock Exchange from 7.1375 pounds Sterling into U.S.
        Dollars has been made at the noon buying rate on November 21,
        2005 of £1=U.S.$ 1.7165. The resulting proposed maximum
        offering price per share, U.S.$ 12.25, has been multiplied
        by the amount of shares to be registered to obtain the proposed maximum
    aggregate offering price of U.S.$ 12,091,452.66.
(4)
On November 25,
        2005, Shire Pharmaceuticals Group plc (the "Predecessor Registrant")
        completed a reorganization (the "Reorganization") of its corporate
        structure through a scheme of arrangement pursuant to Section 425 of
        the United Kingdom Companies Act 1985, resulting in the interposition
        of a new holding company, Shire plc. Pursuant to the scheme of arrangement,
        ordinary shares, each having a nominal value of £3.50, of the Registrant
        were substituted for ordinary shares, each having a nominal value of £0.05,
        of the Predecessor Registrant. Subsequent to the Reorganization and
        in connection therewith, the Registrant will undertake a capital reduction
        resulting in a decrease in the per share nominal value of its ordinary
        shares from £3.50 to £0.05, which is expected to be effective
    on November 29, 2005.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
ITEM 1. PLAN INFORMATION*
ITEM 2. REGISTRANT INFORMATION AND EMPLOYEE PLAN ANNUAL INFORMATION*
*
Information required by Part I of Form S-8 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the Note to Part I of Form S-8.
The documents containing the information specified in Part I will be delivered to the participants in the plan covered by this Registration Statement as required by Rule 428(b). Such documents are not being filed with the Commission as part of this
Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424(b) under the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
The following documents are incorporated herein by reference in this Registration Statement:
(1) The Predecessor Registrant's Annual Report on Form 10-K for the year ended December 31, 2004.
(2) All reports filed by us or by the Predecessor Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since December 31, 2004.
(3) The description of the Registrant's Ordinary Shares contained in the Registrant's Current Report on Form 8-K filed on November 25, 2005, including any amendment or report filed
for the purpose of updating such description.
All other documents filed with the Commission by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date hereof and prior to the filing of a
post-effective amendment which indicates that all securities offered herein have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part
hereof from the date of filing of such documents.
Any statement contained herein or made in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration
Statement to the extent that a statement contained herein, or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 4. DESCRIPTION OF SECURITIES
Not applicable.
ITEM 5. INTEREST OF NAMED EXPERTS AND COUNSEL
None
ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Except as hereinafter set forth, there is no charter provision, by-law, contract, arrangement or statute under which any director or officer of the Registrant is insured or indemnified in any
manner against any liability which he may incur in his capacity as such.
Pursuant to Paragraph 144 of the Articles of Association of the Registrant, every person who was or is a director of the Company may, but is not required to, be indemnified out of the assets of
the Registrant for any liability for which the Company may lawfully indemnify that director.
The Company's Memorandum and Articles of Association provide in relevant part:
Article 144. Indemnity of Directors
Subject to the
    provisions of the Companies Acts, the Company may indemnify any director of
    the
Company or of any associated company against
    any liability and may purchase and maintain for any director of the Company
    or any associated company insurance against any liability.
The relevant provisions of the Companies Act 1985, as amended, are Sections 309A, 309B and 309C, which provide:
"§ 309A: Provisions protecting directors from liability.
(1) This section applies in relation to any liability attaching to a director of a company in connection with any negligence, default, breach of duty or breach of trust by him in relation to
the company.
(2) Any provision which purports to exempt (to any extent) a director of a company from any liability within subsection (1) is void.
(3) Any provision by which a company directly or indirectly provides (to any extent) an indemnity for a director of –
(a) the company, or
(b) an associated company,
against any liability within subsection (1) is void
This is subject to subsections (4) and (5).
(4) Subsection (3) does not apply to a qualifying third party indemnity provision (see section 309B(1)).
(5) Subsection (3) does not prevent a company from purchasing and maintaining for a director of –
(a) the company, or
(b) an associated company,
insurance against any liability within subsection (1).
(6) In this section –
"associated company", in relation to a company ("C"), means a company which is C's subsidiary, or C's holding company or a subsidiary of C's holding company;
"provision" means a provision of any nature, whether or not it is contained in a company's articles or in any contract with a company."
"§ 309B: Qualifying third party indemnity provisions.
2
(1) For the purposes of section 309A(4) a provision is a qualifying third party indemnity provision if it is a provision such as is mentioned in section 309A(3) in relation to which conditions
A to C below are satisfied.
(2) Condition A is that the provision does not provide any indemnity against any liability incurred by the director –
(a) to the company, or
(b) to any associated company.
(3) Condition B is that the provision does not provide any indemnity against any liability incurred by the director to pay –
(a) a fine imposed in criminal proceedings, or
(b) a sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (however arising).
(4) Condition C is that the provision does not provide any indemnity against any liability incurred by the director –
(a) in defending any criminal proceedings in which he is convicted, or
(b) in defending any civil proceedings brought by the company, or an associated company, in which judgment is given against him, or
(c) in connection with any application under any of the following provisions in which the court refuses to grant him relief, namely –
(i) section 144(3) or (4) (acquisition of shares by innocent nominee), or
(ii) section 727 (general power to grant relief in case of honest and reasonable conduct).
(5) In paragraph (a), (b) or (c) of subsection (4) the reference to any such conviction, judgment or refusal of relief is a reference to one that has become final.
(6) For the purposes of subsection (5) a conviction, judgment or refusal of relief becomes final –
(a) if not appealed against, at the end of the period for bringing an appeal, or
(b) if appealed against, at the time when the appeal (or any further appeal) is disposed of.
(7) An appeal is disposed of –
(a) if it is determined and the period for bringing any further appeal has ended, or
(b) if it is abandoned or otherwise ceases to have effect.
(8) In this section "associated company" and "provision" have the same meaning as in section 309A."
"§ 309C: Disclosure of qualifying third party indemnity provisions.
(1) Subsections (2) and (3) impose disclosure requirements in relation to a directors' report under section 234 in respect of a financial year.
(2) If –
3
(a) at the time when the report is approved under section 234A, any qualifying third party indemnity provision (whether made by the company or otherwise) is in force for the benefit of one or
    more directors of the company, or
(b) at any time during the financial year, any such provision was in force for the benefit of one or more persons who were then directors of the company,
the report must state that any such provision is or (as the case may be) was so in force.
(3) If the company has made a qualifying third party indemnity provision and –
(a) at the time when the report is approved under section 234A, any qualifying third party indemnity provision made by the company is in force for the benefit of one or more directors of an
    associated company, or
(b) at any time during the financial year, any such provision was in force for the benefit of one or more persons who were then directors of an associated company,
the report must state that any such provision is or (as the case may be) was so in force.
(4) Subsection (5) applies where a company has made a qualifying third party indemnity provision for the benefit of a director of the company or of an associated company.
(5) Section 318 shall apply to –
(a) the company, and
(b) if the director is a director of an associated company, the associated company,
as if a copy of the provision, or (if it is not in writing) a memorandum setting out its terms, were included in the list of documents in section 318(1).
(6) In this section –
"associated company" and "provision" have the same meaning as in section 309A; and
"qualifying third party indemnity provision" has the meaning given by section 309B(1)."
Shire plc has entered into separate deeds of indemnity with each of its directors, and anticipates entering into deeds of indemnity with directors appointed in future, pursuant to the power under Article 144 of its Articles of Association.
The provisions of the deeds of indemnity are substantially identical and are intended to indemnify the directors of Shire plc to the full extent permitted by Sections 309A, 309B and 309C of the Companies Act 1985 (as amended) (the "Act"), as described above.
The deeds have two key provisions. Under the first (clause 2.1 of each deed), Shire plc indemnifies the director against any "liability" incurred by the director's acts or omissions, or by virtue of his holding office as a director of Shire plc, which arises out of a claim brought against the director by a "third party". "Liability" includes damages awarded against the director by a court (in certain circumstances) and also the cost of defending any claim. A "third party" is any party other than Shire plc, or a company associated with Shire plc. This indemnity is subject to certain limitations to its scope (described in section 309B of the Act) to ensure its qualification as a "third party qualifying indemnity provision" permitted by the Act.
If the director is convicted of a criminal offence or is refused relief by a court in relation to certain applications under the Act, that director must reimburse Shire plc for any amount in respect of the costs of defending the relevant proceedings advanced by Shire plc pursuant to clause 2.1.
Under the second key provision (clause 2.4 of each deed) Shire plc indemnifies the director solely against any liability the director incurs in defending a criminal claim or civil action brought against the director by, or on behalf of, Shire plc or a company associated with Shire plc (the director is not permitted to be indemnified in respect of any liability to Shire plc or an associated company, of itself).
However, the indemnity will cease, and the director will have to reimburse Shire plc for funds paid out under clause 2.4, if the director is convicted in criminal proceedings, if judgment is given against him in civil proceedings, or if he is refused relief by the court in relation to certain applications under the Act.
Shire plc maintains an insurance policy for its directors and officers in respect of liabilities arising out of any act, error or omission while acting in their capacities as directors or
  officers of Shire plc or its affiliated companies.
ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED
Not applicable.
ITEM 8. EXHIBITS
4.1
Memorandum and Articles of Association of Shire plc*
5.1
Opinion of Slaughter and May
23.1
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
23.2
Consent of Slaughter and May (included in Exhibit 5.1)
4
24.1
Powers of attorney (included on the signature pages hereof)
99.1
Shire Pharmaceuticals Group plc Long Term Incentive Plan (as amended and restated on October 22, 2005)
*
Incorporated
by reference to Exhibit 3.01 to Shire's Current Report on Form 8-K filed
with the Securities and Exchange Commission on November 25, 2005.
ITEM 9. REQUIRED UNDERTAKINGS
(a) The undersigned Company hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement to include any material information with respect to the plan of
distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement.
(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company's annual report pursuant to Section 13(a)
or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing
provisions, or otherwise, the Company has been advised that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
5
EXPERTS
The financial statements, the related financial
statement schedules, and management's report on the effectiveness of internal
control over financial reporting incorporated in this  registration statement
by reference from the Annual Report  on Form 10-K of Shire Pharmaceuticals
Group plc for the year ended December 31, 2004 have been audited by Deloitte & Touche
LLP, an independent registered public accounting firm, as stated in their report,
which is incorporated herein by reference, and have been so incorporated in reliance
upon the report of such firm given upon their authority as experts in accounting
and auditing.
6
SIGNATURES
The Registrant, pursuant to the requirements of the Securities Act certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly
caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Basingstoke, England, on this 25
th
day of
November, 2005.
SHIRE PLC
By:
/s/ Matthew Emmens
Name:
Matthew Emmens
Title:
Chief Executive Officer
POWER OF ATTORNEY
Know all men by these presents, that each person whose signature appears below, constitutes and appoints Matthew Emmens and Angus Russell and each of them, our true and lawful attorneys-in-fact
and agents, with full power of substitution and resubstitution, to do any all acts and things and execute, in the name of the undersigned, any and all instruments which said attorneys-in-fact and agents may deem necessary or advisable in order to
enable Shire plc to comply with the Securities Act of 1933, as amended (the "Securities Act"), and any requirements of the Securities and Exchange Commission (the "Commission") in respect thereof, in connection with the filing
with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such
Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, to sign any and all applications, registration statements, notices or
other documents necessary or advisable to comply with applicable state securities laws, and to file the same, together with other documents in connection therewith with the appropriate state securities authorities, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might
or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
7
Signature
Title
Date
/s/ Dr. James Cavanaugh
Chairman and Non-Executive Director
November 25, 2005
Dr. James Cavanaugh
/s/ Matthew Emmens
Chief Executive Officer
November 25, 2005
(Principal
            executive officer)
Matthew Emmens
/s/ Angus Russell
Chief Financial Officer
            (Principal financial
November 25, 2005
officer
            and principal accounting officer)
Angus Russell
/s/ Dr. Barry Price
Senior Non-Executive Director
November 25, 2005
Dr. Barry Price
/s/ The Hon. James A. Grant
Non-Executive Director
November 25, 2005
The Hon. James A. Grant
/s/ Ronald Nordmann
Non-Executive Director
November 25, 2005
Ronald Nordmann
/s/ Robin Buchanan
Non-Executive Director
November 25, 2005
Robin Buchanan
/s/ David Kappler
Non-Executive Director
November 25, 2005
David Kappler
AUTHORIZED US REPRESENTATIVE
/s/ Scott Applebaum
Shire plc
By: Scott Applebaum, as the duly authorized
representative of Shire plc in the United
States
Date:    November 25, 2005
8
EXHIBIT INDEX
4.1
Memorandum and Articles of Association of Shire plc*
5.1
Opinion of Slaughter and May
23.1
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
23.2
Consent of Slaughter and May (included in Exhibit 5.1)
24.1
Powers of attorney (included on the signature pages hereof)
99.1
Shire Pharmaceuticals Group plc Long Term Incentive Plan (as amended and restated on October 22, 2005)
*
Incorporated by
        reference to Exhibit 3.01 to Shire's Current Report on Form 8-K
    filed with the Securities and Exchange Commission on November 25, 2005.
9